Signals
As GLP-1 use scales, dermatology is becoming part of obesity care
A multinational survey presented at EADV 2026 found more self-reported hair, scalp and nail problems among people using GLP-1 receptor agonists than among metabolically similar non-users.
Not All Eye Infections Are Equal: New Evidence Points to a Precision Medicine Approach
What happens when surgeons no longer need to be in the same country as their patients?
EMA backs first oral obesity GLP-1 as pills push treatment towards mass-market adoption
As GLP-1 use expands, healthcare systems are confronting a new challenge: balancing obesity treatment with rising concerns about eating disorders and patient safety.
J&J’s Firefly Bio Deal Puts KRAS Back Into the Oncology Arms Race
Parkinson’s Research Takes Aim at Mitochondrial Failure
Ebola Control Hits the Trust Test
The invisible heart disease crisis: Why congenital heart disease is moving up the global health agenda
A new guideline is changing how health systems think about obesity, diabetes and heart disease
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.